Ikena Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Ikena Oncology's estimated annual revenue is currently $12.6M per year.
- Ikena Oncology's estimated revenue per employee is $202,500
- Ikena Oncology's total funding is $169M.
Employee Data
- Ikena Oncology has 62 Employees.
- Ikena Oncology grew their employee count by -22% last year.
Ikena Oncology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | CFO and Head Corporate Development | Reveal Email/Phone |
5 | Sr. VP Clinical Operations Development | Reveal Email/Phone |
6 | Head Human Resources | Reveal Email/Phone |
7 | VP, Cancer Biology | Reveal Email/Phone |
8 | VP, Program Leadership | Reveal Email/Phone |
9 | Head IT | Reveal Email/Phone |
10 | Head Human Resources | Reveal Email/Phone |
Ikena Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Ikena Oncology?
Ikena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an EP4 receptor antagonist; an AHR antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.. In addition to raising capital from top tier investors OrbiMed Advisors and Atlas Venture, We have entered into a global strategic collaboration with Celgene on the AHR antagonist and Kynase programs. “At Ikena, we begin with the end in mind. We focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.†Mark Manfredi, Chief Executive Officer, Ikena Oncology
keywords:N/A
$169M
Total Funding
62
Number of Employees
$12.6M
Revenue (est)
-22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ikena Oncology News
(Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be...
BioSpace Movers & Shakers, April 15: Spruce, Nautilus, Alto, Ikena Oncology. Published: Apr 15, 2022 By Alex Keown. Leadership. This week, companies and...
The study by Ikena Oncology Inc. is evaluating IK-175 in patients with advanced or metastatic urothelial carcinoma who have progressed on...
Ikena Oncology, Inc. (“Ikena”), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing. The round was led and syndicated by Omega Funds and include ...
BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc., a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing. The round was led and syndicated by Omega Fu ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 62 | 7% | $8.3M |
#2 | $7.2M | 62 | 27% | $2M |
#3 | $7.8M | 62 | 13% | $18M |
#4 | $9.8M | 62 | -7% | $150.1M |
#5 | $7M | 62 | 27% | $62M |